The University of Toledo

Medical College of Ohio

David A Weaver

James C Willey

Erin Crawford

Jeffrey P Demuth

Kristy A Warner

Timothy G Graves

Clara M Jackson

Jeffery P DeMuth

Erin L Crawford

The present invention identifies and quantifies changes in gene expression associated with non-small cell lung cancer NSCLC by examining gene expression in tissue from normal lung and diseased lung. The present invention also identifies and quantifies expression profiles which serve as useful diagnostic markers as well as markers that are useful to monitor disease states, disease progression, drug toxicity, drug efficacy and drug metabolism.

Method for selecting a treatment for non-small cell lung cancer using gene expression profiles

A method measure expression of multiple target genes in a progenitor cell for bronchogenic carcinoma comprising the use of reverse transcription-polymerase chain reaction (RT-PCR) to allow simultaneous expression measurement of the multiple target genes is disclosed.

Method for quantitative measurement of gene expression for identifying individuals at risk for bronchogenic carcinoma

The present invention is directed to methods and compositions for evaluating allelic variations with improved quality controls, methods of preparing such compositions, and applications employing such compositions and methods. In particular, the present invention provides methods and compositions for reducing false positives and/or false negatives in nucleic acid measurements.

Methods and compositions for assessing nucleic acids and alleles

A method and apparatus for quantitative measurement of gene expression through multiplex competitive reverse transcriptase polymerase chain reaction amplification are disclosed. The method and apparatus are especially useful for analysis of small specimens of cells and tissues.

Growing community of inventors

Perrysburg, OH, United States of America

David A Weaver